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Background: A series of drug safety warnings have recently been made by drug authorities relating to adverse
effects of rosiglitazone and pioglitazone on cardiovascular diseases and bladder cancer. The changes to the
patterns of rosiglitazone and pioglitazone utilisation in Australia following the timing of these various health
authority warnings such as the Australian Therapeutic Good Administration (TGA), European Medicines Agency
(EMA) press releases or U.S. Food and Drug Administration (FDA) is unknown. This study investigated the utilisation
patterns of rosiglitazone and pioglitazone in Australia before and after warnings of major drug authorities.
Methods: We evaluated rosiglitazone and pioglitazone dispensing using the Pharmaceutical Benefit Scheme (PBS)
subsidised drug dispensing data for the Australian population from February 2004 to July 2012. The World Health
Organisation Anatomic Therapeutic Chemical (ATC)/Defined Daily Dose (DDD) system was used to compare the
drug utilisation patterns following the announcements of EMA, FDA, and TGA safety warnings, which first occurred
in May 2007. The DDD/1000population/day were examined in a series of time-series regression analysis with the
drug safety warnings specified as interventions.
Results: Rosiglitazone utilisation increased steadily from 2004 until reaching a peak at 1.96/1000population/day in
January 2007. Then rosiglitazone use decreased significantly after the initial EMA press release and FDA warning on
cardiovascular risk in May 2007 (with a 15.04% average monthly decline, p-value <0.001), however use did not
significantly decrease after the TGA warning or subsequent EMA and FDA warnings. Pioglitazone utilisation
proceeded rosiglitazone in September 2008 and remained above 1.5/1000/day during 2009–2010. However,
pioglitazone utilisation has slightly declined after the FDA, EMA, and TGA warnings related to bladder cancer.
Conclusions: Drug safety warnings were associated with a decrease in rosiglitazone and pioglitazone utilisation in
Australia. Rosiglitazone began to decline prior to TGA warnings in December 2007, which suggests that Australian
prescribers may have acted in response to scientific evidence or international safety warnings (EMA, FDA), prior to
the response of the TGA. Minor effects were observed after bladder cancer warnings on pioglitazone utilisation.
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Thiazolidinediones (TZDs) were approved for type 2 dia-
betes mellitus (DM) treatment based on efficacy studies,
which showed a decrease in HbA1c, by 0.8-1.5% and im-
proved insulin sensitivity [1,2]. Both TZDs, rosiglitazone
and pioglitazone, were listed on the Australian Pharma-
ceutical Benefit Scheme (PBS) as subsidised second line* Correspondence: suvimol.niyomnaitham@uq.net.au
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article, unless otherwise stated.therapy with either metformin or a sulfonylurea in
November 2003 and later extended to triple oral therapy
with metformin and a sulfonylurea and in combination
with insulin [3].
In May 2007, a meta-analysis by Nissen and Wolski
found a small increased risk in myocardial infarction and
a borderline increase in cardiovascular death in patients
treated with rosiglitazone [4]; however, another ongoing
clinical trial evaluating cardiovascular outcomes of rosi-
glitazone showed cardiovascular events associated with
rosiglitazone [5] to be inconclusive. Because cardiovas-
cular disease can be a lethal complication in patientsCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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tablish the adverse cardiovascular effect associated with
rosiglitazone treatment [6,7].
Since then, drug regulatory authorities have investigated
these cardiovascular effects [8] and issued several warn-
ings on the use of rosiglitazone [9,10]. The Australian
regulatory authority, the Therapeutic Goods Administra-
tion (TGA) is responsible for ensuring the safety of med-
ical products within Australia [11]. The TGA distributes
safety information to healthcare professionals through
the “Safety Advisory” on the TGA’s website, similar to
that of the U.S. Food and Drug Administration (FDA)
drug safety communication [12] and European Medicines
Agency (EMA) press releases [13].
Since late 2008, PBS steadily limited the subsidisation of
rosiglitazone use in combination with insulin and triple
oral therapy [14]. On 1st July 2011, the PBS restricted
prescription of rosiglitazone by requiring prior telephone
approval [15].
While the meta-analysis raised a concern around the
cardiovascular risk of rosiglitazone, a study of pioglita-
zone showed that in comparison it was a safe alternative
with an insignificant increase in mortality, myocardial
infarction and stroke [16]. Pioglitazone also reduced the
risk of hospitalization for acute myocardial infarction in
patients with type 2 diabetes in comparison with rosigli-
tazone [16,17]. In June 2011, a French study suggested
an increased risk of bladder cancer in patients who were
treated with pioglitazone for more than one year leading
to a temporary withdrawal of pioglitazone by the French
Agency [18]. Another study in the US also indicated a
possible increase in bladder cancer risk in patients on
pioglitazone for more than 2 years, compared with dia-
betes patients who were not receiving pioglitazone [19,20].
The TGA, as well as FDA and EMA, announced safety
warnings outlining a possible risk of bladder cancer re-
lated to pioglitazone use in June-July 2011; however, there
have been no further updates on this issue [21-23].
The increasing risk of cardiovascular disease with
rosiglitazone led to a decrease in the utilisation pat-
terns, in the US [24,25] and some countries in Europe
[26,27]. It is expected that after the bladder cancer
warnings, pioglitazone will follow a similar utilisation
trend to that of rosiglitazone. However, it is plausible
that pioglitazone use may have slightly changed as a re-
sult of prescribers weighing up the benefit in blood
sugar control and prevention of cardiovascular events
versus the possible increased risk of bladder cancer, which
has a very low incidence (3 cases per 1000 pioglitazone
users) [19,20]. The dispensing patterns of rosiglitazone
and pioglitazone following the emerging cardiovascular
event and safety warnings have not been described in
Australia, although it is hypothesised that the trends will
follow that of the US and Europe. This study aims todescribe the patterns of rosiglitazone and pioglitazone use,
and investigate the influential factors on changes of utilisa-
tion in Australia, with special focus on the safety warnings
by TGA, FDA and EMA.Methods
Data sources
Drug utilisation among populations over time can be ex-
amined using the World Health Organization Anatomic
Therapeutic Chemical (ATC)/Defined Daily Dose (DDD)
system [28]. Data on monthly dispensed medicines were
obtained from the PBS database, a national administrative
scheme which records drugs subsidised by the Govern-
ment for Australian citizens. The PBS database captures
all subsidized drug formulations, cost and amount of dis-
pensing and period of drug dispensed by pharmacists for
patients used at home [29]. Drug dispensed data on the
PBS database were used in research studied and shown to
represent trends of drug utilisation in Australia [30,31].
Rosiglitazone and pioglitazone are listed as subsidised
drugs for all Australians therefore a complete record of
dispensed medicines was obtained [3]. Denominator pop-
ulations from Centrelink [32] and the Australian Bureau
of Statistics [33] were used to calculate the DDD per 1000
population per day (the proportion of the population
receiving a DDD of this drug per day). All the data for
this study were aggregated, routinely collected data and
publically available via government sources, therefore
ethics approval was not required.
Australian drug safety warnings for rosiglitazone and
pioglitazone were acquired from safety alerts and safety
information for health professionals on the TGA website
[34]. We accessed the EMA’s safety announcements, called
“press releases” [35], and the FDA drug safety communica-
tion [36] from their official websites. Since mid-2007,
major drug authorities have issued safety warnings related
to rosiglitazone and pioglitazone. The first TGA announce-
ment which highlighted the increased risk of ischemic
heart disease associated with rosiglitazone was issued in
December 2007 (TGA1) [37], followed by a second warn-
ing to avoid using rosiglitazone in patients with ischemic
heart disease in September 2010 (TGA2) [38]. The FDA
had three announcements related to cardiovascular risk of
rosiglitazone [39]; firstly, a safety alert in May 2007 (FDA1)
[40], a label update on heart-related risks in August 2007
(FDA2) [41], and then restrictions on rosiglitazone use in
September 2010 (FDA3) [42]. There were four EMA press
releases on risk of ischemic heart disease in May 2007
(EMA1) [43], October 2007 (EMA2) [44], January 2008
(EMA3) [45] and September 2010 (EMA4) [46]. While the
TGA and FDA still allowed rosiglitazone on the market,
the EMA suspended all medical products containing rosi-
glitazone across Europe in September 2010 [46].
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increased risk of bladder cancer in patients who used pio-
glitazone for longer than one year in June 2011 [23],
followed by the same warnings in the EMA press release
[21] and the TGA safety advisory [22] in July 2011.
Whilst there were other plausible types of information
sent to prescribers with regards to the drug safety, it is
recognized that the warnings from the FDA, EMA and
TGA have a large influence on drug safety communica-
tion. For example, the pharmaceutical companies market-
ing these medicines did not implement changes to the
Product Information until after the TGA announcement.
In Australia, medical media picked up this side effect once
it came out from the FDA as well as medical associations
issued the FDA warning on their articles.
Analyses
Monthly dispensing data of rosiglitazone and pioglita-
zone from January 2004 to July 2012 were converted to
DDD/1000population/day. Descriptive trends in rosigli-
tazone and pioglitazone utilisation were examined in the
time series of DDD/1000pop/day. The auto-regressive,
integrated, moving average model (ARIMA) integrates
the temporal size and direction dependency (autocorrel-
ation) inherent in time-series data to better characterize
changes in data over a period of time [47]. Autocorrel-
ation functions (ACF) and partial autocorrelation func-
tions (PACF) was used to obtain the best fitted model
for analysis as well as the Bayesian Information Criteria.
The percentage change in DDD/1000pop/day was used
to remove the trend component of the time series before
fitting into ARIMA models. The separate and combined
effects of the announcement of the EMA, FDA, and
TGA warnings on trends in rosiglitazone and pioglitazone
utilisation were also investigated by fitting into ARIMA
models. Impacts of drug safety warnings (interventions)
on the subsequent observations were then investigated
using the ARIMA model as a step-function (having a per-
manent and immediate impact on any subsequent trends).
All statistical analyses were performed with a 5% statistical
significance level using STATA 12.1 (StataCorp, College
Station, TX).
Results
A total of 1,686,087 rosiglitazone prescriptions and
2,405,881 pioglitazone prescriptions were dispensed dur-
ing January 2004-July 2012. We calculated the monthly
utilisation (DDD/1000population/day) using Australian
population data, which was in the range of 20.1 million
in 2004–22.9 million in 2012. As shown in Figure 1, the
rosiglitazone utilisation increased steadily from 2004 and
reached the peak in January 2007 with a defined daily
dose of 1.96 per 1000 people per day. However, in May
2007, the trend of rosiglitazone utilisation starteddecreasing and remaining lower than 0.50 DDD/
1000pop/day in May 2009 and 0.15 DDD/1000pop/day
in July 2011. Pioglitazone utlisation has exceeded rosigli-
tazone use since September 2008 and remained stable
during 2009–2010 (1.5-1.7 DDD/1000pop/day). Never-
theless, the trend of pioglitazone utilisation appeared to
decrease in September 2011.
There are no seasonal autocorrelation detected for
both rosiglitazone and pioglitazone utilisations. Based on
visual inspection of PACF and ACF plots, an ARIMA
(1,0,2) model best characterised for rosiglitazone data
and pioglitazone data was best characterised as an
ARIMA (1,0,1). Findings from ARIMA models indicated
that the utilisation of rosiglitazone decreased signifi-
cantly after the EMA1 and FDA1 warnings with −15.04%
per month (p-value <0.001) (Table 1). Additionally, the
utilisation of rosiglitazone also significantly decreased fol-
lowing warnings from FDA2, EMA2, TGA1, and EMA3.
However, after adjustment for FDA2, EMA2, TGA1, and
EMA3 for preceding warnings, effects were attenuated
and were no longer statistically significant (Table 1). Later
warnings relating to EMA4, FDA3, and TGA2 were not
significantly associated with decreases in rosiglitazone
use (Table 1).
For pioglitazone, although we can see a decline after
the FDA, TGA, and EMA warnings on bladder cancer in
June-July 2011, there is no statistically significant effect
on subsequent pioglitazone use after fitting this into
ARIMA model (Table 1).
Discussion
The changes of rosiglitazone and pioglitazone utilisation
were observed between 2004 and 2012 in Australia. It is
always difficult to attribute cause to utilisation trends,
however it is likely that increased marketing of TZDs
may have contributed to the increasing trend of rosigli-
tazone during 2004–2006 or that fewer alternatives to
metformin, sulfonylurea, and insulin were available at
this time. Our results show a decreasing trend in rosigli-
tazone utilisation in the period after the drug authorities’
warnings in 2007–2008. Although the numbers of rosi-
glitazone prescriptions in Australia are relatively low in
comparison to the UK, and North America, the overall
trends are consistent with those shown in Europe and
North America [24,26,27,48]. There are two possible ex-
planations for the dip seen in April 2007. It might be a
seasonal trend as the same fluctuation was noted in
March-April 2006; however, this was not sensitive
enough to be detected by the ARIMA model. Secondly,
the dip is an artifact of the data, this is actually the util-
isation on its way up which is demonstrated by the
higher use again in May 2007.
The sharply decreasing utilisation trend is significantly
attributable to the safety alert from meta-analysis study
Figure 1 Utilisation of rosiglitazone and pioglitazone by the Australian population between 2004–2012. The drop-down lines indicate
months of drug safety warnings issued. Notes: Rosiglitazone warnings: EMA1-Reminded the risk of rosiglitazone in patients with cardiac failure
and other cardiac disorders including myocardial infarction. FDA1-Advised to evaluate the antidiabetic treatment options other than rosiglitazone
in patients who have underlying heart disease and high risk of heart attack. FDA2-Adds box warnings for heart-related risks of rosiglitazone.
EMA2-Suggested that rosiglitazone should only be used after careful evaluation of ischemic heart disease. TGA1-dvised that rosiglitazone should
not be prescribed for patients with known ischemic heart disease or at high risk for ischemic heart disease. EMA3-Suggested that rosiglitazone
must not be used in patients with an acute coronary disease. EMA4-Recommended suspension of all rosiglitazone-containing products. FDA3-Restricts
access to rosiglitazone due to an elevated risk of cardiovascular events. TGA3-Reinforced that rosiglitazone should not be used in patients with known
ischemic heart disease. Pioglitazone warnings: FDA-Announced the warnings on a possibly increased risk of bladder cancer in patients who used
rosiglitazone for longer than one year. TGA-Advised the prescribers that use of pioglitazone for more than a year may be associated with an
increased risk of bladder cancer. EMA-Recommends new contraindications and warnings for pioglitazone to reduce small increased risk of
bladder cancer. TGA = Therapeutic Good Administration; EMA = European Medicines Agency; FDA = U.S. Food and Drug Administration.
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2007. For the reason that the FDA issued the cardiovas-
cular alert of rosiglitazone on the same day as publication
by Nissen et al. [4], we could not distinguish the effects
between the authority warnings and the publication.Table 1 Effects of drug warnings on the utilisation of rosiglita
Drug authorities Time Warnings Adjusted f
Rosiglitazone: ARIMA (1,0,2) model
EMA1_FDA1 May 2007 Ischemic heart
FDA2 Aug 2007 Label update heart related EMA1_FDA
EMA2 Oct 2007 Ischemic heart EMA1_FDA
TGA1 Dec 2007 Ischemic heart EMA1_FDA
EMA3 Jan 2008 Ischemic heart EMA1_FDA
FDA3, TGA2, EMA4 Sep 2010 EU suspended, EMA1_FDA
US restriction
Pioglitazone: ARIMA (1,0,1) model
FDA June 2011 Bladder cancer
EMA, TGA July 2011 Bladder cancer
aCoefficient = Percentage change in magnitude and direction after the intervention
bCI = confidence interval.
cStatistical significance at p value <0.05.
TGA = Therapeutic Good Administration; EMA = European Medicines Agency; FDA
of America.Furthermore, the effects of these warnings and associ-
ated literature are likely to be cumulative rather than a
discrete effect on the following utilisation. Several re-
strictions in rosiglitazone subsidies from the PBS during
October 2008-Febraury 2009 were also examined; however,zone and pioglitazone in Australia
or Coefficienta 95% CIb p value
- −15.04 [−21.86, −8.22] <0.001c
1 −2.61 [−40.41, 35.20] 0.893
1, FDA2 1.94 [−95.49, 99.36] 0.969
1, FDA2, EMA2 −5.25 [−38.01, 27.51] 0.837
1, FDA2, EMA2, TGA1 −0.39 [−80.06, 79.28] 0.992
1, FDA2, EMA2, TGA1, EMA3 1.25 [−8.99, 11.49] 0.811
- −5.76 [−13.91, 2.39] 0.166
- −6.57 [−14.80, 1.65] 0.117
.
= U.S. Food and Drug Administration; EU = European Union; US = United States
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previous warnings. As a result of the consecutive series
of cardiovascular warnings on rosiglitazone since 2007
and the limited access on PBS, the numbers of rosiglita-
zone prescriptions have remained lower than 5,000 per
month since 2010.
Australian utilisation of pioglitazone was less than half
of rosiglitazone during 2005–2007 and the increasing
trend in use was moderate compared to the Netherlands
and the US [25,27]. From 2008–2010, when peak levels
were reached, the increase in pioglitazone nearly mirrors
the decline in rosiglitazone. The findings suggest that
prescribers might have replaced rosiglitazone with the
same drug class pioglitazone [24,49], due to the reported
cardiovascular benefits of pioglitazone, and no clinical
outcome associated with an increase risk of ischemic
heart disease that was seen with rosiglitazone [7,17].
While the decreasing trend of pioglitazone was observed
in the US and Europe in 2008 [27,49], Australian pioglit-
azone utilisation plateaued until 2011. The delay in de-
creasing trend compared to that of other countries may
be attribute to limited availability of second-line and
third-line therapy alternatives such as sitagliptin (was not
PBS subsidised until August 2008) or exenatide (was not
PBS subsidised until August 2010) [50]. The US and UK
data [49,51] show that the number of other new drugs,
which were available in their markets since 2007 such as
sitagliptin and exenatide, increased after the cardiovascu-
lar alerts of TZD. Nevertheless, Figure 1 shows the decline
in the utilisation of pioglitazone after July 2011. This de-
creasing trend may have been caused by more alternative
treatments on the PBS or the safety concern of increased
risk of bladder cancer in long-term users of pioglitazone.
Although, this decline was of a lesser magnitude than
for rosiglitazone, prescribers may consider the risk/benefit
ratio, where the benefits of pioglitazone in lowering blood
sugar outweigh the possible risk of bladder cancer [52].
However, more data points following this bladder cancer
risk might be needed to examine the true effect of this
warning.
Since TGA safety warnings are considered by the
Australian Department of Health and Aging to be first-
line alerts to Australian prescribers, we would expect to
see a significant effect on these utilisations. However, the
fact that a) the decline in rosiglitazone use occurred prior
to the first TGA warning, and b) after we adjusted for the
preceding EMA, FDA warnings, we could not see a sig-
nificant effect of the TGA warning on utilisation trends
suggests that Australian prescribers were aware of the
international warnings as well as the safety information
from the literature. This might be associated with the way
that information was delivered, since Australian warnings
were delayed, less frequently communicated, and accessed
compared to the FDA and European warnings [38,53].Australian prescribers may receive safety information
from medical articles or media that referred to the US
or European warnings. A further qualitative study is being
conduct to gain the insight into sources of drug safety
information among Australian prescribers.
Since time series model prediction is based on the pat-
tern of drug use in the past confounding influences on
data may be difficult to disentangle. Although trends can
be impacted by temporal changes in drug supply or the
way data are recorded, we did not find those problems
during study period. Furthermore, the Australia PBS data
is aggregated data collected for administrative purposes,
which does not link utilisation to the prescribing data in
clinical settings. Therefore, clinical reasons for the de-
crease in dispensing cannot be fully investigated, nor
primary non-compliance in patients be established.
The strength of this study is that it captures almost all
prescriptions dispensed over 2004–2012 in total Australian
population (private prescriptions represent a very small
percentage of all prescriptions). This is achieved because
rosiglitazone and pioglitazone are ‘high’ cost drugs that are
government subsidised in Australia. This allowed us to in-
vestigate the patterns of population based thiazolidine-
dione utilisation.Conclusions
The utilisation of rosiglitazone significantly decreased fol-
lowing the authorities’ safety warnings on ischemic heart
disease. The pattern of rosiglitazone utilisation started de-
clining significantly prior to the TGA warning in December
2007; therefore it appears that Australian prescribers were
alerted by the literature and international warnings such
as EMA and FDA. In contrast, pioglitazone utilisation in-
creased during the rosiglitazone warning period during
2007–2010. In comparison to the US and Europe, the de-
cline in pioglitazone trend was much more deferred due
to no available second and third line therapies in Australia.
Despite concerns surrounding the possible risk of bladder
cancer with long term use of pioglitazone, this study
showed weaker effects of safety warnings on bladder can-
cer and pioglitazone utilisation. A number of publications
have studied the effect of authorities’ warnings in the US
and Europe to improve their warning systems [27,54,55].
This is one of the first studies to date that has investigated
utilisation patterns in relation to drug safety warnings in
Australia and suggests that TGA warnings may not affect
prescribing in cases such as this where prescribers may be
attuned to particular medicine safety issues described in
earlier international warnings or literature. Further re-
search is needed to understand how and when prescribers
obtain drug safety information in Australia. This is par-
ticularly pertinent as Australia and New Zealand look to
combine their drug safety warning systems.
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